Download PDF
Horm Metab Res 2018; 50(09): 690-695
DOI: 10.1055/a-0649-8010
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Panhypopituitarism Without GH Replacement: About Insulin Sensitivity, CRP Levels, and Metabolic Syndrome

Alejandro Rosell Castillo
1   Endocrinology Division, Department of Clinical Medicine, University of Campinas, Campinas, São Paulo, Brazil
,
Denise Engelbrecht Zantut-Wittmann
1   Endocrinology Division, Department of Clinical Medicine, University of Campinas, Campinas, São Paulo, Brazil
,
Arnaldo Moura Neto
1   Endocrinology Division, Department of Clinical Medicine, University of Campinas, Campinas, São Paulo, Brazil
,
Rodrigo Menezes Jales
2   Imaging Division, Department of Obstetrics and Gynecology, University of Campinas, Campinas, São Paulo, Brazil
,
Heraldo Mendes Garmes
1   Endocrinology Division, Department of Clinical Medicine, University of Campinas, Campinas, São Paulo, Brazil
› Author Affiliations
Further Information

Publication History

received 22 March 2018

accepted 19 June 2018

Publication Date:
05 September 2018 (online)

Also available at
   Permissions and Reprints

Abstract

A complete deficiency of anterior pituitary hormones from several etiologies characterizes Panhypopituitarism (PH). Despite advances in treatment, patients with PH maintain high rates of morbidity and mortality, a reason to investigate some insulin sensitivity, metabolic and inflammatory parameters that could be related to the increase of these indicators. This was a cross-sectional study comprising 41 PH patients under hormonal replacement, except for growth hormone, and 37 individuals in a control group (CG) with similar age, gender and body mass index (BMI). We assessed clinical data as age, sex, BMI, waist circumference, waist/hip ratio (WHR), history of hypertension, diabetes mellitus and dyslipidemia as well as fasting glycaemia, insulin, HOMA-IR, HbA1c, high-sensitivity CRP (hs-CRP), and lipid profile. PH patients presents lower values of glycaemia, insulin, HOMA-IR (0.88 vs 2.1) and WHR, but higher levels of hs-CRP (0.38 vs 0.16mg/dl) when compared with the CG. Although the occurrence of dyslipidemia was higher in patients with PH, the frequency of metabolic syndrome was similar between the groups. In multivariate linear regression analysis, the PH group independently predicted lower HOMA-IR and WHR values. In conclusion, this study demonstrated that patients with PH without GH replacement have lower HOMA-IR and WHR values and higher levels of hs-CRP than a CG paired by age, gender and BMI. The diagnosis of dyslipidemia was more frequent in patients with PH, but the occurrence of MS was similar to CG. Further studies are needed to confirm our findings and to better understand the metabolic characteristics of patients with PH.

Key words

insulin resistance - hypopituitarism - inflammatory activity - dyslipidemia
 

  • References

  • 1 Toogood AA, Stewart PM. Hypopituitarism: Clinical features, diagnosis, and management. Endocrinol Metab Clin North Am 2008; 37: 235-261
    CrossrefPubMedSearch in Google Scholar
  • 2 Ascoli P, Cavagnini F. Hypopituitarism. Pituitary 2006; 9: 335-342
    CrossrefPubMedSearch in Google Scholar
  • 3 Jasim S. et al Mortality in adults with hypopituitarism: a systematic review and meta-analysis. Endocrine 2017; 6: 33-42
    PubMedSearch in Google Scholar
  • 4 Bhat MA. et al Insulin resistance, metabolic syndrome and chronic low-grade inflammation in Sheehan’s syndrome on standard replacement therapy: a case control study. Pituitary 2015; 18: 312-318
    CrossrefPubMedSearch in Google Scholar
  • 5 Johansson JO. et al Growth hormone-deficient adults are insulin resistant. Metabolism 1995; 44: 1126-1129
    CrossrefPubMedSearch in Google Scholar
  • 6 Ciresi A, Amato MC, Giordano C. Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment. J Endocrinol Invest 2014; 38: 351-359
    PubMedSearch in Google Scholar
  • 7 Pena Bello L. et al Circulating Levels of Irisin in Hypopituitary and Normal Subjects. PLoS One 2016; 29: 11
    PubMedSearch in Google Scholar
  • 8 Johansson JO, Landin K, Tengborn L, Rosén T, Bengtsson BA. High fibrinogen and plasminogen activator inhibitor activity in growth hormone deficient adults. Arterioscler Thromb 1994; 14: 434-437
    CrossrefPubMedSearch in Google Scholar
  • 9 Leonsson M, Hulthe J, Johannsson G, Wiklund O, Wikstrand J, Bengtsson BA, Oscarsson J. Increased interleukin-6 levels in pituitary-deficient patients are independently related to their carotic intima-media thickness. Clin Endocrinol Oxf 2003; 59: 242-250
    CrossrefPubMedSearch in Google Scholar
  • 10 Lehmann ED. et al Aortic distensibility in growth hormone deficient adults. Lancet 1993; 341: 309
    CrossrefPubMedSearch in Google Scholar
  • 11 Markussis V. et al Detection of premature atherosclerosis by high-resolution ultrasonography in symptom- free hypopituitary adults. Lancet 1992; 340: 1188-1192
    CrossrefPubMedSearch in Google Scholar
  • 12 Rosén T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-288
    CrossrefPubMedSearch in Google Scholar
  • 13 Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996; 81: 1169-1172
    PubMedSearch in Google Scholar
  • 14 Bülow B. et al Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol Oxf 1997; 46: 75-81
    CrossrefPubMedSearch in Google Scholar
  • 15 Bates AS. et al Life expectancy following surgery for pituitary tumors. Clin Endocrinol Oxf 1999; 50: 315-319
    CrossrefPubMedSearch in Google Scholar
  • 16 Tomlinson JW. et al Association between premature mortality and hypopituitarism. Lancet 2001; 357: 425-431
    CrossrefPubMedSearch in Google Scholar
  • 17 Beshyah SA. et al Metabolic abnormalities in growth hormone deficient adults: Carbohydrate tolerance and lipid metabolism. Endocrinol Metab 1994; 1: 173-180
    PubMedSearch in Google Scholar
  • 18 Abs R. et al GH replacement in 1034 growth hormone deficient adults: Demographic and clinical characteristics, dosing and safety. Clin Endocrinol Oxf 1999; 50: 703-713
    CrossrefPubMedSearch in Google Scholar
  • 19 Abdu TA. et al Coronary risk in growth hormone deficient hypopituitary adults: Increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol Oxf 2001; 55: 209-216
    CrossrefPubMedSearch in Google Scholar
  • 20 Beshyah SA. et al Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin Endocrinol Oxf 1995; 42: 179-189
    CrossrefPubMedSearch in Google Scholar
  • 21 Lönn L. et al Body composition and tissue distributions in growth hormone deficient adults before and after growth hormone treatment. Obes Res 1996; 4: 45-54
    CrossrefPubMedSearch in Google Scholar
  • 22 Jørgensen JO. et al Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989; 1: 1221-1225
    PubMedSearch in Google Scholar
  • 23 Khang AR. et al Sex differences in the prevalence of metabolic syndrome and its components in hypopituitary patients: Comparison with an age- and sex-matched nationwide control group. Pituitary 2016; 19: 573-581
    CrossrefPubMedSearch in Google Scholar
  • 24 Verhelst J. et al Prevalence and characteristics of the metabolic Syndrome in 2479 Hypopituitary patients with adult-onset GH deficiency before GH replacement: A KIMS analysis. Eur J Endocrinol 2011; 165: 881-889
    CrossrefPubMedSearch in Google Scholar
  • 25 Nyenwe EA. et al Nonalcoholic fatty liver disease and metabolic syndrome in hypopituitary patients. Am J Med Sci 2009; 338: 190-195
    CrossrefPubMedSearch in Google Scholar
  • 26 Rosen T. et al Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol Oxf 1993; 38: 63-71
    CrossrefPubMedSearch in Google Scholar
  • 27 Binnerts A. et al Lamberts SW. Body composition in growth hormone-deficient adults. Am J Clin Nutr 1992; 55: 918-923
    PubMedSearch in Google Scholar
  • 28 Salomon F. et al The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: 1797-1803
    CrossrefPubMedSearch in Google Scholar
  • 29 Fleseriu M. et al Hormonal replacement in hypopituitarism in adults: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 3888-3921
    CrossrefPubMedSearch in Google Scholar
  • 30 Alberti KG. et al Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity,”. Circulation 2009; 120: 1640-1645
    CrossrefPubMedSearch in Google Scholar
  • 31 Cambiaso P. et al Nocturnal hypoglycaemia in ACTH and GH deficient children: Role of continuous glucose monitoring. Clin Endocrinol Oxf 2013; 79: 232-237
    CrossrefPubMedSearch in Google Scholar
  • 32 Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009; 30: 152-177
    CrossrefPubMedSearch in Google Scholar
  • 33 Pia A. et al A rare case of adulthood-onset growth hormone deficiency presenting as sporadic, symptomatic hypoglycemia. J Endocrinol Invest 2004; 27: 1060-1064
    CrossrefPubMedSearch in Google Scholar
  • 34 O'Neill BT, Lauritzen HP, Hirshman MF, Smyth G, Goodyear LJ, Kahn CR. Differential Role of Insulin/IGF-1 Receptor Signaling in Muscle Growth and Glucose Homeostasis. Cell Rep 2015; 11: 1220-1235
    CrossrefPubMedSearch in Google Scholar
  • 35 Ronnemaa T. et al Glucose metabolism in identical twins discordant for obesity. The critical role of visceral fat. J Clin Endocrinol Metab 1997; 82: 383-387
    PubMedSearch in Google Scholar
  • 36 Hong JW. et al Metabolic parameters and nonalcoholic fatty liver disease in Hypopituitarism. Horm Metab Res 2011; 1: 48-54
    Thieme ConnectPubMedSearch in Google Scholar
  • 37 Young JA, List EO, Kopchick JJ. Deconstructing the Growth Hormone Receptor (GHR): Physical and Metabolic Phenotypes of Tissue-Specific GHR Gene-Disrupted Mice. Prog Mol Biol Transl Sci 2016; 138: 27-39
    PubMedSearch in Google Scholar
  • 38 Guevara AJ, Guevara A, Bahamonde M. Insulin resistance depends on GH counter-regulation in two syndromes of short stature. Growth Horm IGF Res 2018; 38: 44-48
    CrossrefPubMedSearch in Google Scholar
  • 39 Sesmilo G, Miller KK, Hayden D, Klibanski A. Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab 2001; 86: 5774-5781
    CrossrefPubMedSearch in Google Scholar
  • 40 Filipsson Nyström H. et al Discontinuing long-term GH replacement therapy – a randomized, placebo-controlled crossover trial in adult GH deficiency. J Clin Endocrinol Metab 2012; 97: 3185-3195
    CrossrefPubMedSearch in Google Scholar
  • 41 Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 2000; 133: 111-122
    CrossrefPubMedSearch in Google Scholar
  • 42 Rudling M. et al Regulation of rat hepatic low density lipoprotein receptors. In vivo stimulation by growth hormone is not mediated by insulin-like growth factor-I. J Clin Invest 1996; 97: 292-299
    CrossrefPubMedSearch in Google Scholar
  • 43 Lind S. et al Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. Arterioscler Thromb Vasc Biol 2004; 24: 349-356
    CrossrefPubMedSearch in Google Scholar
  • 44 Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. Am J cardiol 2012; 110: 823-825
    CrossrefPubMedSearch in Google Scholar
  • 45 Kearney T. et al Hypopituitarism is associated with triglyceride enrichment of very low density lipoprotein. J Clin Endocrinol Metab 2001; 86: 3900-3906
    CrossrefPubMedSearch in Google Scholar
  • 46 Han TS. et al Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia. Clin Endocrinol Oxf 2013; 78: 197-203
    CrossrefPubMedSearch in Google Scholar
  • 47 Attanasio AF. et al Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab 2010; 95: 74-81
    CrossrefPubMedSearch in Google Scholar
  • 48 Cavagioni LC. et al Metabolic Syndrome in professional truck drivers who work on Highway BR-116 within the area of São Paulo City – Régis Bittencourt”. Arq Bras Endocrinol Metabol 2008; 52: 1015-1023
    CrossrefPubMedSearch in Google Scholar
  • 49 Meigs JB. Epidemiology of the metabolic syndrome. Am J of Manag Care 2002; 8: 283-292
    PubMedSearch in Google Scholar
  • 50 Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88: 2404-2411
    CrossrefPubMedSearch in Google Scholar
  • 51 Benetti Pinto CL. et al Leptin and adiponectin blood levels in women with premature ovarian failure and age- and weight-matched women with normal menstrual cycles. Menopause 2010; 17: 174-177
    CrossrefPubMedSearch in Google Scholar